GTG.AX - Genetic Technologies Limited

ASX - ASX Delayed price. Currency in AUD

Genetic Technologies Limited

60-66 Hanover Street
Fitzroy, VIC 3065
Australia
61 3 8412 7000
http://www.gtglabs.com

SectorHealthcare
IndustryMedical Laboratories & Research
Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Jerzy MuchnickiChairman & Interim CEO89.68kN/AN/A
Mr. Paul Keith Mathieson Viney B. Bus, FCPA, FGIA, FCIConsultant180.45kN/AN/A
Mr. Phillip Hains C.A., M.B.A., B Bus, CA, MBAChief Financial OfficerN/AN/AN/A
Mr. Justyn StedwellCompany Sec.N/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. The company also engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. In addition, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.

Corporate governance

Genetic Technologies Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.